 |
인쇄하기
취소
|
Daiichi Sankyo, “Olmesartan’s removal of insurance benefit is not revocation of approval”
“The de
cision is only removal from the insurance benefit, not revocation of approval. We will continue adjusting domestic actions with the Ministry of Food and Drug Safety.”
When it came to the olmesartan’s French expulsion crisis, Daiichi Sankyo finally left a comment.
On the 11th, the Ministry of Food and Drug Safety(MFDS)s announced the French healthcare authorities decided to remove olmes...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.